LEADER 00924nam a2200253 a 4500 001 991003813579707536 008 020 $a9780190274559 035 $ab14391752-39ule_inst 040 $aDip.to di Storia, Societą e Studi sull'Uomo$bita 082 0 $a 303.484 245 14$aThe Oxford handbook of the radical right /$cedited by Jens Rydgren 260 $aNew York :$bOxford University Press,$c2018 300 $aXIX, 734 p. ;$c26 cm 490 0 $aOxford handbooks 650 $aConservatorismo 650 4$aRadicalismo 700 1 $aRydgren, Jens 907 $a.b14391752$b01-09-20$c11-06-20 912 $a991003813579707536 945 $aLE023 303.484 OXF 1 1$g1$i2023000185483$lle023$op$pE134.90$q-$rl$so $t0$u0$v0$w0$x0$y.i15932412$z29-07-20 996 $aOxford handbook of the radical right$91755284 997 $aUNISALENTO 998 $ale023$b11-06-20$cm$da $e-$feng$git $h4$i0 LEADER 04858nam 22006015 450 001 9910254558403321 005 20200702165428.0 010 $a4-431-55031-3 024 7 $a10.1007/978-4-431-55031-0 035 $a(CKB)3150000000021361 035 $a(EBL)4419966 035 $a(SSID)ssj0001653537 035 $a(PQKBManifestationID)16432940 035 $a(PQKBTitleCode)TC0001653537 035 $a(PQKBWorkID)14982666 035 $a(PQKB)10826546 035 $a(DE-He213)978-4-431-55031-0 035 $a(MiAaPQ)EBC4419966 035 $a(PPN)192217534 035 $a(EXLCZ)993150000000021361 100 $a20160222d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aImmunotherapy of Cancer $eAn Innovative Treatment Comes of Age /$fedited by Yoshiyuki Yamaguchi 205 $a1st ed. 2016. 210 1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2016. 215 $a1 online resource (351 p.) 300 $aDescription based upon print version of record. 311 $a4-431-55030-5 320 $aIncludes bibliographical references. 327 $aPart I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 ??-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 ?? T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. 330 $aThis timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival. 606 $aOncology   606 $aCancer research 606 $aImmunology 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 615 0$aOncology  . 615 0$aCancer research. 615 0$aImmunology. 615 14$aOncology. 615 24$aCancer Research. 615 24$aImmunology. 676 $a616.994079 702 $aYamaguchi$b Yoshiyuki$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910254558403321 996 $aImmunotherapy of Cancer$92519904 997 $aUNINA LEADER 02938oam 2200529M 450 001 9910135957903321 005 20240501142930.0 010 $a1-351-81773-6 010 $a1-315-21315-X 010 $a1-351-81774-4 024 7 $a10.4324/9781315213156 035 $a(CKB)3710000000912489 035 $a(MiAaPQ)EBC4717841 035 $a970383598 035 $a(OCoLC)962413689 035 $a(OCoLC-P)962413689 035 $a(FlBoTFG)9781315213156 035 $a(EXLCZ)993710000000912489 100 $a20161205d2016 fy 0 101 0 $aeng 135 $aur||||||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aGrace Meets Grit $eHow to Bring Out the Remarkable, Courageous Leader Within /$fDaina Middleton 205 $a1st ed. 210 1$a[Place of publication not identified] :$cRoutledge,$d2016. 215 $a1 online resource (225 pages) $cillustrations 311 08$a1-62956-139-8 320 $aIncludes bibliographical references and index. 327 $apt. 1. Gender differences in leadership style -- pt. 2. The leadership behaviors. 330 $aThere is no mistaking that inequality in the workplace is still prevalent in the form of salary inequity and unequal representation in leadership and board positions. Too often conversations about inequality can lead to men and women believing they are alike. Women and men are not the same, biologically or psychologically, and these differences lead to significant dissimilarities in how each approaches leadership situations. Grace Meets Grit navigates the previously unexplored subject of gender differences in the workplace specifically applied to critical leadership behaviors. Leadership behaviors are what make us all successful in the workplace. They are how we are evaluated against our peers and what we use to solve problems when working in teams. We also know that the most effective organizations work diligently to optimize these leadership behaviors. Through stories of extraordinary, courageous women, Grace Meets Grit shows how to compensate for your innate style by "dialing up" leadership qualities you may not naturally possess. Middleton empowers women, in particular, to embrace their innate qualities and anticipate and apply behaviors expected of their male counterparts to help level the playing field. The end result is fewer misunderstandings in the workplace and higher performance from both individual leaders and teams. 606 $aLeadership 606 $aLeadership in women 606 $aWomen$xPsychology 615 0$aLeadership. 615 0$aLeadership in women. 615 0$aWomen$xPsychology. 676 $a658.4092082 686 $aBUS071000$2bisacsh 700 $aMiddleton$b Daina$0929949 801 0$bOCoLC-P 801 1$bOCoLC-P 906 $aBOOK 912 $a9910135957903321 996 $aGrace meets grit$92091147 997 $aUNINA